TargetMol

Rodorubicin

Product Code:
 
TAR-T26113
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26113-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rodorubicin is a novel tetraglycosidic anthracycline with antitumor activity.
CAS:
96497-67-5
Formula:
C48H64N2O17
Molecular Weight:
941.037
Purity:
0.98
SMILES:
[H][C@]12C[C@H](O[C@@H]3[C@H](C)O[C@H](C[C@@H]3N(C)C)O[C@H]3C[C@](O)(CC)[C@H](O[C@H]4C[C@@H]([C@H](O)[C@H](C)O4)N(C)C)c4c(O)c5C(=O)c6cccc(O)c6C(=O)c5c(O)c34)O[C@@H](C)[C@@]1([H])O[C@]1([H])O[C@@H](C)C(=O)C[C@@]1([H])O2

References

1. Kraemer HP, Sedlacek HH. Rodorubicin, a new tetraglycosidic anthracycline. Behring Inst Mitt. 1988 Apr;(82):216-30. PubMed PMID: 3165634. 2. Verweij J, van der Burg ME, van Putten WL, Henzen-Logmans SC, Salewski E, Kraemer HP, Stoter G. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. Eur J Cancer Clin Oncol. 1989 Apr;25(4):627-32. PubMed PMID: 2714339. 3. Hermentin P, Doenges R, Gronski P, Bosslet K, Kraemer HP, Hoffmann D, Zilg H, Steinstraesser A, Schwarz A, Kuhlmann L, et al. Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge region of monoclonal antibodies. Bioconjug Chem. 1990 Mar-Apr;1(2):100-7. PubMed PMID: 2095207. 4. Iwahashi T, Tone Y, Usui J, Watanabe H, Sugawara I, Mori S, Okazaki H. Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208. Cancer Immunol Immunother. 1989;30(4):239-46. PubMed PMID: 2598192.